CASI Pharmaceuticals, Inc.
August 04, 2025 - by Joey Ramson
$CASI, a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases, announced today the FDA clearance of an IND application for CID-103. An anti-CD38 monoclonal antibody in adults with active and chronic active renal allograft antibody mediated rejection.
